Open AccessEfficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors
Author(s) -
ChengLun Lai,
TienHua Chen,
Peter MuHsin Chang,
Shyh–Kuan Tai,
PenYuan Chu,
Muh–Hwa Yang
Publication year - 2022
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000740
Subject(s) - cetuximab , medicine , oncology , regimen , pembrolizumab , head and neck squamous cell carcinoma , head and neck cancer , progression free survival , adverse effect , cancer , immunotherapy , chemotherapy , colorectal cancer
The antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab and immune checkpoint inhibitors (ICIs) are the current front-line treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, understanding of the efficacy of cetuximab-containing regimens in patients who fail ICI treatments is limited. In this study, we present the efficacy of cetuximab-based regimens in heavily pretreated R/M HNSCC patients after progression to ICIs.